Home » Topics » BioWorld Science

BioWorld Science
RSS

Improved pharmacokinetic properties of trans-translation inhibitors efficacious against gonorrhea

June 14, 2018

CFDA grants priority review to Pharnext's PXT-3003 for CMT1A

June 14, 2018

FDA approves moxidectin to treat river blindness

June 14, 2018

First-in-human data demonstrate early signs of antitumor activity for BI-836880

June 14, 2018

Flex Pharma stops two phase II clinical studies of FLX-787

June 14, 2018

Vistusertib administration feasible prior to radical prostatectomy

June 14, 2018

First patient dosed in phase I study of MET-409

June 14, 2018

Researchers present phase I data for neoadjuvant anti-OX40 therapy with MEDI-6469 in HNSCC

June 14, 2018

Seattle Genetics doses first patient in phase II study of tisotumab vedotin for cervical cancer

June 14, 2018

Application for Furoscix receives complete response letter from the FDA

June 14, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...